阿司匹林对冠心病患者血小板释放反应的影响

Effects of aspirin on platelet releasing reaction of patients with coronary heart disease

采用放射免疫法测定 40例冠心病 ( CHD)患者口服单剂阿司匹林 ( ASA) 40 mg( 2 0例 )与 30 0 mg( 2 0例 )前后血浆 β血小板球蛋白 ( β- TG)、前列环素 ( PGI2 )产物 6-酮 - PGF1α及血栓素 ( TXA2 )产物 TXB2 。结果表明 :40 mg ASA组 2 4 h血浆 β- TG明显减少 ( P <0 .0 5) ,血浆 TXB2 1 2 h与 2 4 h均非常显著下降 (P <0 .0 1 ) ,而血浆 6-酮 - PGF1α无明显变化 ;30 0 mg ASA组除 6-酮 - PGF1α显著减少外 ,血浆 β- TG及 TXB2变化态势同 40 mg组 ,提示口服单剂 40 mg与 30 0 mg ASA均能显著阻抑血小板释放反应 ;30 0 mg ASA可使体内 PGI2 含量减少 ,未能改善 CHD患者 PGI2 /TXA2 平衡。

We measured quantitatively β TG, 6 keto PGF 1α and TXB 2 in plasma of 40 volunteers with stable coronary heart disease with radioimmunoassay before and after taken aspirin(ASA) 40mg(20 cases) and 300mg(20 cases) orally. The results showed the contents of TXB 2 and β TG in plasma were remarkably declined at 12 and/or 24 hours, but the contents of 6 keto PGF 1α were not changed in 40mg group patients; and reducing trends of β TG and TXB 2 contents in two group patients were similar, but the contents of 6 keto PGF 1α in the group taken 300mg ASA were remarkably decreased. Conclusion was that ASA taken orally would remarkably inhibit platelet releasing reaction relating to decrease of TXA 2 in organism.